Navigation Links
Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
Date:4/2/2009

CHARLOTTESVILLE, Virginia, April 2 /PRNewswire/ -- Biovista Inc. today announced that BVA-101, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-101, an existing drug that Biovista repositioned in MS and is aimed at neuroprotection, was shown to have both efficacy in reducing symptoms and no toxic effects in this well established model of MS.

"We are excited about these early results that confirm the predictive capability of our repositioning platform technology and encourage us to further develop this compound in a disease area where there is a significant need for new therapies" said Aris Persidis, Ph.D., President of Biovista. "What is also encouraging is that we reached this stage just 4 months after deciding to work in MS. At the present time we are exploring all options available to us, including the further co-development with a pharmaceutical company and the licensing of the IP to a generics company" Dr. Persidis added.

About Biovista's BVA-101 trial in the MS EAE-MOG model

MS is a chronic inflammatory disease of the CNS with unknown etiology. It is the most frequent non-traumatic disabling neurologic disease among young adults, with 12,000 new diagnoses per year in the US alone, and over 2.5 million patients worldwide. In the animal proof of concept trial, BVA-101 was compared to dexamethasone, a potent anti-inflammatory and immunosuppressive drug that is efficient in accelerating the recovery from MS relapses but too toxic for chronic use. BVA-101 induced a statistically significant reduction of EAE severity, the magnitude of which was statistically similar to that caused by dexamethasone.

About Biovista's repositioning pipeline and technology platform

Biovista applies high-throughput discovery efforts to finding solutions for commerci
'/>"/>

SOURCE Biovista Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... SAN CARLOS, Calif. , March 3, 2015 /PRNewswire/ ... with expertise in drug-disease modeling and simulation research, today ... during the 2015 American Society for Clinical Pharmacology and ... March 3-7 2015.   Logo - ... and Rosa will present a poster describing a ...
(Date:3/3/2015)... 2015 Becht Engineering Co., Inc., ... has acquired The CECON Group, Inc., located in ... not announced. , Becht Engineering (http://www.becht.com ) ... including oil and gas production, refining, petrochemical, chemical, ... power sectors. The company has twelve offices in ...
(Date:3/3/2015)... 2015 Research and Markets ( ... PharmaBiotech,s new report "Personalized Medicine - Scientific ... , The aim of personalized medicine ... drug to the right patient and, in some ... a patient according to his/her genotype. This report ...
(Date:3/3/2015)... FRANCISCO , March 3, 2015  Johnson & ... @ South San Francisco (JLABS @SSF), ... Boulevard, South San Francisco, Calif. ... accommodate up to 50 startups from across the healthcare ... health.  The first resident startups have ...
Breaking Biology Technology:Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 2Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 3Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 2Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 2Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 4Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 5
... May 13 A guide to BRCA1 and ... resource is designed to equip physicians and other healthcare professionals who are ... the complexities of BRCA1/2 gene testing. , ... According to the American Cancer Society, ...
... TIANJIN, China , May 13 /PRNewswire-Asia/ -- A ... of,Biotechnology and Medicine (TJAB) and Genzyme Corporation was held in the,Tianjin ... , , ... executives including Rao Zihe, President of TJAB and,President of Nankai University, ...
... May 13  Fibrocell Science, Inc. (OTC Bulletin ... of autologous cell therapies for aesthetic, medical and scientific ... study (IT-H-001) of azficel-T, an autologous cell therapy currently ... (FDA) for the treatment of moderate to severe nasolabial ...
Cached Biology Technology:Hayes, Inc. Releases Guide to BRCA1 and BRCA2 Genetic Testing 2Tianjin International Joint Academy of Biotechnology and Medicine, Genzyme Enter into Strategic Partnership 2Fibrocell Science, Inc. Initiates Histology Study of azficel-T 2Fibrocell Science, Inc. Initiates Histology Study of azficel-T 3
(Date:3/2/2015)... --  Neurotechnology , a provider of high-precision biometric, robotics ... Development Kit (SDK). The SentiGaze algorithm enables designers ... to track eye movements and generate heatmaps based on ... be used for applications such as analysis of websites ... can also be used to develop interfaces for a ...
(Date:2/24/2015)... Feb. 24, 2015 Research and Markets ... of the "Global 2D Gesture Recognition Market ... The analysts forecast the Global 2D Gesture ... 32.12% over the period 2014-2019 The ... sectors is one of the major trends in ...
(Date:2/13/2015)... 2015 ACT Genomics Co., Ltd., a ... transform cancer genomic information into precision diagnosis and ... raised US$ 8 million in the its first private ... Taipei, Taiwan , ACT Genomics has developed ... aim to implement next generation sequencing (NGS) and ...
Breaking Biology News(10 mins):Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2ACT Genomics Raises $8 Million in its First Private Funding Round 2
... photosynthesis, it's good to think "outside the bun." , That's ... Arts & Sciences at Washington University in St. Louis, did ... his collaborators at Lawrence Berkeley National Laboratory and the University ... taco shell protein. , Taco shell protein ...
... "backup" brain region springs into action to compensate for disruption ... finding offers new insight into how the brains of stroke ... of movement. , Jacinta O'Shea and colleagues at the University ... issue of the journal Neuron, published by Cell Press. ...
... The antiviral drug peramivir might offer humans significant protection ... according to results of mouse studies conducted by investigators ... Peramivir, an antiviral drug, blocks the ability of influenza ... the release of new virus particles and their spread ...
Cached Biology News:Protein enables discovery of quantum effect in photosynthesis 2Protein enables discovery of quantum effect in photosynthesis 3How the brain's backup system compensates for stroke 2Peramivir protects mice from lethal H5N1 infection 2
Acetate Plate Sealers 100/Box...
... is a concentrated formulation of a rinsing ... action technology, as well as for manual ... David Brigati M.D., Department of Pathology, University ... is recommended for all the rinsing steps ...
... The standard of the Axima ... of high mass accuracy, resolution, sensitivity ... versatility with both linear and reflectron ... field reflectron enables the generation of ...
Rat Aortic Smooth Muscle Cells (RAOSMC) (>500,000 cells)...
Biology Products: